MK-5661
Total Payments
$119,026
Transactions
2
Doctors
1
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $118,026 | 1 | 0 |
| 2019 | $1,000 | 1 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $118,026 | 1 | 99.2% |
| Consulting Fee | $1,000 | 1 | 0.8% |
Payments by Type
Research
$118,026
1 transactions
General
$1,000
1 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Single-Ascending-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-5661 in Healthy Participants | Merck Sharp & Dohme Corporation | $118,026 | 0 |
Top Doctors Receiving Payments for MK-5661
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Boston, MA | $118,026 | 1 |
| , MD SCD | Nephrology | Boston, MA | $1,000 | 1 |
Ad
Manufacturing Companies
- Merck Sharp & Dohme Corporation $119,026
Product Information
- Type Drug
- Total Payments $119,026
- Total Doctors 1
- Transactions 2
About MK-5661
MK-5661 is a drug associated with $119,026 in payments to 1 healthcare providers, recorded across 2 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2019 to 2020. In 2020, $118,026 was paid across 1 transactions to 0 doctors.
The most common payment nature for MK-5661 is "Unspecified" ($118,026, 99.2% of total).
MK-5661 is associated with 1 research study, including "A Single-Ascending-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-5661 in Healthy Participants" ($118,026).